Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 615
- Registration Number
- NCT02715726
- Locations
- 🇨🇳
Investigational Site Number 1560018, Beijing, China
🇨🇳Investigational Site Number 1560008, Hangzhou, China
🇨🇳Investigational Site Number 1560009, Shenyang, China
Randomized Trial Comparing Colesevelam vs. Ezetimibe
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Target Recruit Count
- 200
- Registration Number
- NCT02682680
- Locations
- 🇨🇦
LMC Barrie, Barrie, Ontario, Canada
🇨🇦LMC Brampton, Brampton, Ontario, Canada
🇨🇦LMC Calgary, Calgary, Alberta, Canada
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
- Conditions
- Interventions
- First Posted Date
- 2015-12-30
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 413
- Registration Number
- NCT02642159
- Locations
- 🇺🇸
Investigational Site Number 840-156, Tustin, California, United States
🇫🇮Investigational Site Number 246101, Oulu, Finland
🇺🇸Investigational Site Number 840-118, Los Angeles, California, United States
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT02634580
- Locations
- 🇯🇵
Research Site, Shinagawa-ku, Tokyo, Japan
Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 998
- Registration Number
- NCT02476006
- Locations
- 🇦🇹
Investigational Site Number 040001, Graz, Austria
🇦🇹Investigational Site Number 040002, Wien, Austria
🇦🇹Investigational Site Number 040010, Wien, Austria
Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana
- Target Recruit Count
- 42
- Registration Number
- NCT02304926
to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- NVP Healthcare
- Target Recruit Count
- 59
- Registration Number
- NCT02289430
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 149
- Registration Number
- NCT02260648
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Federal University of Rio Grande do Sul
- Target Recruit Count
- 52
- Registration Number
- NCT02234544
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol
- Conditions
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 366
- Registration Number
- NCT02227784
- Locations
- 🇺🇸
Alan Graff, MD, PA, Fort Lauderdale, Florida, United States
🇺🇸Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Maryland Cardiovascular Specialists, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.